{
    "nctId": "NCT01223833",
    "briefTitle": "A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors and Tamoxifen",
    "officialTitle": "A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Third-generation Aromatase Inhibitors and Tamoxifen",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Arthralgia",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 296,
    "primaryOutcomeMeasure": "To assess the effect of BMI on loss of grip strength measured by a modified sphygmomanometer with baseline, month 3, month 6 and month 12 measurements.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with early breast cancer who are scheduled to receive endocrine therapy with tamoxifen or any of the third-generation aromatase inhibitors, anastrozole, letrozole or exemestane.\n2. No major rheumatological disorders such as severe rheumatoid arthritis.\n3. Patients must have provided informed consent for participation in this study.\n\nExclusion Criteria:\n\n1. Concomitant endocrine therapy for breast cancer.\n2. Concomitant intake of sex hormone containing drugs such as hormone replacement therapy.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}